Mercer Global Advisors
CVS icon

Mercer Global Advisors’s CVS Health CVS Stock Holding History

Mercer Global Advisors’s Portfolio CVS Stock Details CVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.6M Buy
151,163
+5,316
+4% +$475K 0.02% 436
2026
Q1 		$10.5M Buy
145,847
+4,711
+3% +$363K 0.02% 485
2025
Q4 		$11.2M Buy
141,136
+15,396
+12% +$1.21M 0.02% 464
2025
Q3 		$9.48M Buy
125,740
+30,306
+32% +$2.08M 0.02% 477
2025
Q2 		$6.58M Buy
95,434
+10,079
+12% +$661K 0.01% 500
2025
Q1 		$5.78M Sell
85,355
-29,898
-26% -$1.79M 0.01% 504
2024
Q4 		$5.17M Buy
115,253
+2,785
+2% +$156K 0.01% 530
2024
Q3 		$6.92M Sell
112,468
-6,113
-5% -$357K 0.02% 415
2024
Q2 		$7.51M Sell
118,581
-1,385
-1% -$86.6K 0.02% 362
2024
Q1 		$9.57M Sell
119,966
-18,281
-13% -$1.4M 0.03% 320
2023
Q4 		$10.9M Sell
138,247
-5,547
-4% -$395K 0.03% 293
2023
Q3 		$10M Sell
143,794
-38,835
-21% -$2.75M 0.04% 272
2023
Q2 		$12.6M Sell
182,629
-27,845
-13% -$1.98M 0.05% 245
2023
Q1 		$15.6M Sell
210,474
-102,701
-33% -$8.61M 0.07% 198
2022
Q4 		$29.2M Buy
313,175
+30,689
+11% +$2.96M 0.15% 110
2022
Q3 		$26.9M Buy
282,486
+23,720
+9% +$2.35M 0.16% 98
2022
Q2 		$24M Buy
258,766
+7,209
+3% +$704K 0.15% 110
2022
Q1 		$25.5M Buy
251,557
+28,551
+13% +$3M 0.15% 107
2021
Q4 		$23M Buy
223,006
+9,165
+4% +$847K 0.14% 115
2021
Q3 		$18.1M Buy
213,841
+16,882
+9% +$1.41M 0.13% 139
2021
Q2 		$16.4M Buy
196,959
+47,797
+32% +$3.91M 0.13% 126
2021
Q1 		$11.2M Buy
149,162
+47,470
+47% +$3.46M 0.1% 154
2020
Q4 		$6.95M Buy
101,692
+9,765
+11% +$635K 0.09% 176
2020
Q3 		$5.37M Buy
91,927
+1,085
+1% +$67.5K 0.08% 188
2020
Q2 		$5.9M Buy
90,842
+51,387
+130% +$3.24M 0.11% 139
2020
Q1 		$2.34M Sell
39,455
-10,807
-22% -$721K 0.05% 293
2019
Q4 		$3.73M Sell
50,262
-4,622
-8% -$325K 0.07% 215
2019
Q3 		$3.46M Sell
54,884
-1,158
-2% -$68.6K 0.08% 198
2019
Q2 		$3.05M Buy
56,042
+5,644
+11% +$304K 0.08% 202
2019
Q1 		$2.72M Buy
+50,398
New +$3.11M 0.1% 187

Other funds holding CVS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Mercer Global Advisors's CVS Position: Q2 2026 in Review

Mercer Global Advisors increased its CVS Health (CVS) stake by 3.6% in Q2 2026, buying an estimated $475K and bringing the position to 151,163 shares worth $15.6M. The position accounts for 0.02% of the portfolio, ranked #436.

Mercer Global Advisors first reported a position in CVS in Q1 2019 and has held it in 30 quarters since. The position peaked at $29.2M in Q4 2022. 2,068 funds tracked by Wall St. Rank hold CVS as of Q2 2026.

  • Mercer Global Advisors held 151,163 shares of CVS Health worth $15.6M as of Q2 2026.
  • Mercer Global Advisors bought 5,316 CVS Health shares in Q2 2026, an estimated $475K.
  • CVS Health made up 0.02% of Mercer Global Advisors's portfolio in Q2 2026, its #436 holding.
  • Mercer Global Advisors first reported a position in CVS Health in Q1 2019 and has held it in 30 quarters since.
  • Mercer Global Advisors's CVS Health position peaked at $29.2M in Q4 2022.
  • 2,068 funds tracked by Wall St. Rank held CVS Health as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.